NCT05519865 2026-04-20
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Phase 2 Completed
Chipscreen Biosciences, Ltd.
BeOne Medicines
BeOne Medicines
BeiGene
BeiGene
BeiGene
BeiGene
BeiGene
Sun Yat-sen University